The US Institute for Clinical and Economic Review (ICER) has posted a draft scoping document on its planned review of the cost-effectiveness offered by Vertex Pharmaceuticals’ (Nasdaq: VRTX) cystic fibrosis (CF) drugs in the USA.
In its review, The ICER will consider the triple combination therapy elexacaftor/tezacaftor/ivacaftor, which is currently under review by the US Food and Drug Administration, to estimate what would be a fair price in light of data on clinical effectiveness.
The cost-effectiveness body will also examine new data that has become available since its May 2018 review of Symdeko (tezacaftor/ivacaftor), Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze